Pharmaceutical Industry Information Portal

HomeNewsletter

Newsletter

FDA Approves alpelisib as first and only treatment for PROS, a spectrum of rare conditions

Novartis on Wednesday announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Vijoice® (alpelisib) for the treatment of adult and...

Pfizer expands RSV portfolio by acquiring ReViral for up to $525 million

Pfizer Inc. and ReViral Ltd. announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately...

Sandoz, Ares Genetics expand digital alliance in antimicrobial resistance

Sandoz announces the extension and expansion of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global...

Bioxcell Therapeutics announces FDA approval of IGALMI, the first new acute treatment for schizophrenia or bipolar disorder

BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify and develop transformative medicines in neuroscience and immuno-oncology, on Wednesday announced...

Evonetix attains thermal control technology for DNA synthesis patent

Evonetix Ltd, the synthetic biology company bringing semiconductor technology to DNA synthesis, on Monday announced it has been granted patent in Europe for its...

Venatorx Pharmaceuticals raises to support its portfolio of novel antibacterial drugs

Venatorx Pharmaceuticals, Inc., a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, on...
spot_img

Expert Articles

spot_img